Institution
Barts Health NHS Trust
Healthcare•London, United Kingdom•
About: Barts Health NHS Trust is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Medicine. The organization has 3483 authors who have published 3807 publications receiving 81829 citations.
Papers published on a yearly basis
Papers
More filters
••
University of Bristol1, University Hospitals of Leicester NHS Trust2, University of Leicester3, The Royal Marsden NHS Foundation Trust4, Papworth Hospital5, Barts Health NHS Trust6, Beatson West of Scotland Cancer Centre7, Gartnavel General Hospital8, Aneurin Bevan University Health Board9, Blackpool Victoria Hospital10, Golden Jubilee National Hospital11, New Cross Hospital12, South Tees Hospitals NHS Trust13, Leeds Teaching Hospitals NHS Trust14, Colchester Hospital University NHS Foundation Trust15, Clatterbridge Cancer Centre NHS Foundation Trust16, Maidstone and Tunbridge Wells NHS Trust17, Norfolk and Norwich University Hospital18, University of Oxford19
TL;DR: The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effectiveness and cost-effectiveness of surgery—(extended) pleurectomy decortication—versus no surgery for the treatment of pleural mesothelioma and will test the hypothesis that surgery and chemotherapy is superior to chemotherapy alone with respect to overall survival.
Abstract: Introduction Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality of life. Currently, only two surgical trials have been performed which found that neither extensive (extra-pleural pneumonectomy) or limited (partial pleurectomy) surgery improved survival (although there was some evidence of improved quality of life). Therefore, clinicians are now looking to evaluate pleurectomy decortication, the only radical treatment option left. Methods and analysis The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effectiveness and cost-effectiveness of surgery—(extended) pleurectomy decortication—versus no surgery for the treatment of pleural mesothelioma. The study will test the hypothesis that surgery and chemotherapy is superior to chemotherapy alone with respect to overall survival. Secondary outcomes include health-related quality of life, progression-free survival, measures of safety (adverse events) and resource use to 2 years. The QuinteT Recruitment Intervention is integrated into the trial to optimise recruitment. Ethics and dissemination Research ethics approval was granted by London – Camberwell St. Giles Research Ethics Committee (reference 13/LO/1481) on 7 November 2013. We will submit the results for publication in a peer-reviewed journal. Trial registration numbers ISRCTN—ISRCTN44351742 and ClinicalTrials.gov—NCT02040272.
31 citations
••
TL;DR: Patients older than 75 years are less likely to be seen within the target waiting time, according to a retrospectively analyzed analysis of all adult attendances to 9 EDs within the Paris area during 2011.
31 citations
••
TL;DR: While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%‐40% and were suboptimal for all groups, highlighting the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials.
Abstract: Allos pharmaceuticals
Associazione Angela Serra per la Ricerca sul Cancro
Associazione Italiana per la Ricerca sul Cancro (AIRC)
Fondazione Cassa di Risparmio di Modena
Fondazione Italiana Linfomi
Spectrum Pharmaceuticals
NCI CCSG
P30 CA008748
31 citations
••
TL;DR: Plasma-Lyte in the perioperative period is safe in renal transplantation and is associated with a favourable biochemical profile, including a reduced incidence of hyperkalaemia, better diuresis and less frequent use of renal replacement therapy early after surgery.
Abstract: Background Kidney transplant recipients often receive large volumes of intravenous fluid replacement in the peri-operative period. Administration of 0.9% saline has previously been associated with acidosis, hyperkalaemia and acute kidney injury. The perioperative use of physiologically balanced replacement fluids may reduce the incidence of post-operative renal replacement therapy and hyperkalaemia. Methods A retrospective review of consecutive renal transplants before and after a change in perioperative fluid prescription from 0.9% saline to Plasma-Lyte 148. Results A total of 97 patients were included in the study, 59 receiving exclusively 0.9% saline and 38 receiving exclusively Plasma-Lyte. Patients in the Plasma-Lyte group were less likely to require emergency postoperative dialysis than those receiving 0.9% saline [odds ratio (OR) 0.15 (95% confidence interval 0.03-0.48), P = 0.004], and these patients had more favourable biochemical parameters with less hyperkalaemia, less acidosis and better diuresis. Patients in the Plasma-Lyte group also had a shorter length of hospital stay (7 days versus 11 days; P < 0.0001) and better graft function at 3 months postoperatively (estimated glomerular filtration rate 51 versus 44 mL/min/1.73 m2; P = 0.03); however, there was no difference in graft function at 1 year. Conclusions Plasma-Lyte in the perioperative period is safe in renal transplantation and is associated with a favourable biochemical profile, including a reduced incidence of hyperkalaemia, better diuresis and less frequent use of renal replacement therapy early after surgery. In patients receiving Plasma-Lyte, graft function was better at 3 months, but this difference did not persist up to 1 year after transplantation.
31 citations
••
TL;DR: Two sessions of the workshop during the XIX meeting of the European Association for Haematopathology (EAHP) held in Edinburgh in September 2018 dedicated to lymphomas of the gastrointestinal tract showed the usefulness of novel molecular diagnostic methods such as targeted NGS to identify high-risk genetic features with potential clinical impact.
Abstract: This paper summarizes two sessions of the workshop during the XIX meeting of the European Association for Haematopathology (EAHP) held in Edinburgh in September 2018 dedicated to lymphomas of the gastrointestinal tract. The first session focused on the clinical and pathological features of primary gastrointestinal T cell and NK-cell lymphoproliferative disorders. The distinction between precursor lesions (RCD type 2) and enteropathy-associated T cell lymphoma were stressed, including the discussion of new diagnostic markers for the identification of aberrant phenotypes. Indolent T cell lymphoproliferative disorders of the gastrointestinal tract cases showed phenotypic heterogeneity with novel molecular alterations in few cases, such as STAT3-JAK2 fusion. In addition, novel clonal markers of disease, such as AXL and JAK3 somatic variants support the neoplastic nature of NK-cell enteropathy. The session on gastrointestinal tract B cell lymphoproliferations was dedicated to B cell lymphoproliferative disorders that arise primarily in the gastrointestinal tract (i.e., duodenal-type follicular lymphoma) or preferentially involve the digestive tract, such as large B cell lymphoma with IRF4 translocation and mantle cell lymphoma (MCL), including diverse molecular subtypes (i.e., CCND3-positive MCL mimicking MALT lymphoma). Challenging cases of high-grade B cell lymphomas with complex genetic profiles demonstrated the usefulness of novel molecular diagnostic methods such as targeted NGS to identify high-risk genetic features with potential clinical impact.
31 citations
Authors
Showing all 3516 results
Name | H-index | Papers | Citations |
---|---|---|---|
James F. Wilson | 146 | 677 | 101883 |
Donna Neuberg | 135 | 810 | 72653 |
Stephen G. Ellis | 127 | 655 | 65073 |
John E. Deanfield | 120 | 497 | 61067 |
Nicola Maffulli | 115 | 1570 | 59548 |
Mark J. Caulfield | 113 | 362 | 95358 |
Perry M. Elliott | 107 | 560 | 65814 |
Jadwiga A. Wedzicha | 104 | 505 | 49160 |
Andrew V. Schally | 102 | 1107 | 50314 |
Patricia B. Munroe | 94 | 339 | 62378 |
Khalid S. Khan | 92 | 684 | 33700 |
Gavin Giovannoni | 89 | 852 | 38443 |
Christoph Thiemermann | 89 | 474 | 28732 |
Thomas T. MacDonald | 87 | 340 | 25611 |
Abba J. Kastin | 87 | 598 | 32864 |